Biotech · Private company
Pearl Therapeutics, Inc.
Track this companyFree. Adds Pearl Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials110 recruiting or active
Pipeline programs30From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline30
- BD MDI 320 μgPhase 3 · Chronic Obstructive Pulmonary DisorderClinicalTrials.gov · fetched Nov 12, 2026
- BFF MDI (PT009) 160/9.6 μgPhase 3 · Chronic Obstructive Pulmonary DisorderClinicalTrials.gov · fetched Nov 12, 2026
- BFF MDI (PT009) 320/9.6 μgPhase 3 · COPDClinicalTrials.gov · fetched Nov 12, 2026
- BFF MDI (PT009) 320/9.6 μgPhase 3 · Chronic Obstructive Pulmonary DisorderClinicalTrials.gov · fetched Nov 12, 2026
- BFF MDI 160/9.6 μgPhase 3 · Chronic Obstructive Pulmonary DisorderClinicalTrials.gov · fetched Nov 12, 2026
- BFF MDI 320/9.6 μgPhase 3 · COPDClinicalTrials.gov · fetched Nov 12, 2026
- BFF MDI 320/9.6 μgPhase 3 · Chronic Obstructive Pulmonary DisorderClinicalTrials.gov · fetched Nov 12, 2026
- BGF MDI 160/14.4/9.6 μgPhase 3 · COPDClinicalTrials.gov · fetched Nov 12, 2026
- BGF MDI 320/14.4/9.6 μgPhase 3 · COPDClinicalTrials.gov · fetched Nov 12, 2026
- FF MDI (PT005)Phase 3 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- FF MDI (PT005) 9.6 μgPhase 3 · Chronic Obstructive Pulmonary DisorderClinicalTrials.gov · fetched Nov 12, 2026
- FF MDI 9.6 μgPhase 3 · Chronic Obstructive Pulmonary DisorderClinicalTrials.gov · fetched Nov 12, 2026
- GFF MDI (PT003)Phase 3 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- GFF MDI (PT003)Phase 3 · COPDClinicalTrials.gov · fetched Nov 12, 2026
- GFF MDI (PT003) 14.4/9.6 μgPhase 3 · COPDClinicalTrials.gov · fetched Nov 12, 2026
- GFF MDI 14.4/9.6 μgPhase 3 · COPDClinicalTrials.gov · fetched Nov 12, 2026
- GP MDI (PT001)Phase 3 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- GP MDI 14.4 μgPhase 3 · AsthmaClinicalTrials.gov · fetched Nov 12, 2026
- GP MDI 28.8 μgPhase 3 · AsthmaClinicalTrials.gov · fetched Nov 12, 2026
- GP MDI 7.2 μgPhase 3 · AsthmaClinicalTrials.gov · fetched Nov 12, 2026
- Spiriva Respimat 2.5 μgPhase 3 · AsthmaClinicalTrials.gov · fetched Nov 12, 2026
- Symbicort® TBH 400/12 μg BIDPhase 3 · Chronic Obstructive Pulmonary DisorderClinicalTrials.gov · fetched Nov 12, 2026
- Symbicort® Turbuhaler® (TBH) Inhalation PowderPhase 3 · COPDClinicalTrials.gov · fetched Nov 12, 2026
- AZD 2115, Dose 2Phase 2 · Chronic Obstructive Pulmonary Disease (COPD)ClinicalTrials.gov · fetched Nov 12, 2026
- AZD2115 Dose 1Phase 2 · Chronic Obstructive Pulmonary Disease (COPD)ClinicalTrials.gov · fetched Nov 12, 2026
- PT010Phase 1 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Regimen APhase 1 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Regimen BPhase 1 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Regimen CPhase 1 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Regimen DPhase 1 · Chronic Obstructive Pulmonary DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant AsthmaPHASE2_PHASE3 · COMPLETED · started Dec 13, 2017ClinicalTrials.gov NCT03358147 · fetched Nov 12, 2026
- A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010PHASE1 · COMPLETED · started Oct 17, 2017ClinicalTrials.gov NCT03311373 · fetched Nov 12, 2026
- A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat DosePHASE1 · COMPLETED · started Aug 11, 2017ClinicalTrials.gov NCT03250182 · fetched Nov 12, 2026
- Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPDPHASE3 · TERMINATED · started Dec 9, 2016ClinicalTrials.gov NCT02685293 · fetched Nov 12, 2026
- Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPDPHASE3 · COMPLETED · started May 31, 2016ClinicalTrials.gov NCT02766608 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)PHASE3 · COMPLETED · started Apr 29, 2016ClinicalTrials.gov NCT02727660 · fetched Nov 12, 2026
- Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary DiseasePHASE3 · COMPLETED · started Aug 10, 2015ClinicalTrials.gov NCT02536508 · fetched Nov 12, 2026
- A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)PHASE3 · COMPLETED · started Aug 10, 2015ClinicalTrials.gov NCT02497001 · fetched Nov 12, 2026
- Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)PHASE3 · COMPLETED · started Jun 30, 2015ClinicalTrials.gov NCT02465567 · fetched Nov 12, 2026
- Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPDPHASE3 · COMPLETED · started Mar 30, 2015ClinicalTrials.gov NCT02343458 · fetched Nov 12, 2026
- Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPDPHASE2 · COMPLETED · started May 1, 2014ClinicalTrials.gov NCT02109406 · fetched Nov 12, 2026